Diagnostic value of antibodies to modified citrullinated vimentin in early rheumatoid arthritis

Human Immunology

Volumn 73, Issue 4, 2012, Pages 389-392

  Sizova, Lyudmila ^a  

^a ORENBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Anti MCV; Diagnosis; Early rheumatoid arthritis; IgM RF

Indexed keywords

ANTIBODY; C REACTIVE PROTEIN; IMMUNOGLOBULIN M; MODIFIED CITRULLINATED VIMENTIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOGRAPHY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; VISUAL ANALOG SCALE;

ANTIBODIES; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; VIMENTIN;

EID: 84859080793     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.01.007     Document Type: Article

References (18)

1. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid Arthritis Classification Criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 62:1580-1588.
2. Després N., Boire G., Lopez-Longo F.J., Ménard H.A. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994, 21:1027-1033.
3. Nicaise Roland P., Gorrtenboer Mignot S., Bruns A., Hurtado M., Palazzo E., Hayem G., et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Res Ther 2008, 10:R142.
4. van Venrooij W.J., Hazes J.M., Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. J Med 2002, 60:383-388.
5. Innala L., Kokkonen H., Eriksson C., Jidell E., Berglin E., Dahlqvist S.R. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008, 35:1002-1008.
6. Bang H., Egerer K., Gauliard A., Lüthke K., Rudolph P.E., Fredenhagen G., et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007, 56:2503-2511.
7. Emery P., Breedveld F.C., Dougados M., Kalden J.R., Schiff M.H., Smolen J.S. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002, 61:290-297.
8. Steinbrocker O., Traeger C.H., Batterman R.C. Therapeutic criteria in rheumatoid arthritis. JAMA 1949, 140:659-662.
9. Hochberg M.C., Chang R.W., Dwosh I., Lindsey S., Pincus T., Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992, 35:498-502.
10. van Steendam K., Tilleman K., Deforce D. The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatol (Oxford) 2011, 50:830-870.
11. Damjanovska L., Thabet M.M., Levarth E.W., Stoeken-Rijsbergen G., van der Voort E.I., Toes R.E., et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 2010, 69:730-732.
12. Liu X., Jia R., Zhao J., Li Z. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis. J Rheumatol 2009, 36:1136-1142.
13. Raza K., Mathsson L., Buckley C.D., Filer A., Rönnelid J. Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis. Ann Rheum Dis 2010, 69:627-628.
14. Mathsson L., Mullazehi M., Wick M.C., Sjöberg O., van Vollenhoven R., Klareskog L., et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arhritis Rheum 2008, 58:36-45.
15. Ursum J., Nielen M.M., van Schaardenburg D., van der Horst A.R., van de Stadt R.J., Dijkmans B.A., et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 2008, 10:R12.
16. Wagner E., Skoumal M., Bayer P.M., Klaushofer K. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int 2009, 29:1315-1321.
17. Dejaco C., Klotz W., Larcher H., Duftner C., Schirmer M., Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in arthritis. Arthritis Res Ther 2006, 8:R119.
18. Sahin O., Kaptanoglu E., Bakici M.Z., Sezer H., Elden H., Hizmetli S. Dianostic value of autoantibodies against citrullinated peptide antigens in rheumatoid arthritis: comparison of different commercial kits. Turk J Rheumatol 2011, 26:13-18.